source
- Gilead invests up to $1.87 B in Vir Biotechnology for three T-cell engagersGilead Sciences announced a licensing agreement with Vir Biotechnology that includes an equity investment and potential milestone payments totalling up to $1.87 billion. The upfront component is $…
- Verastem reports robust response in pancreatic cancer subgroup where Revolution's drug laggedVerastem Oncology announced that its KRAS G12D‑targeting inhibitor VS‑7375 showed strong activity in a Phase 1/2 trial that includes patients with advanced solid tumors. In the pancreatic cancer co…